Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Initiation of appropriate treatment helps restore Vitamin B12 levels and alleviates anemia-related symptoms
present in ~40% of PV patients Plethora (facial redness/ruddy complexion) due to increased RBC mass and skin hyperemia Headache, dizziness, and visual disturbances from hyperviscosity and reduced cerebral blood flow Splenomegaly palpable in 7090% of PV patients from extramedullary hematopoiesis Thrombotic events (DVT, stroke, MI, Budd-Chiari syndrome) major complications from hyperviscosity Erythromelalgia burning pain/redness of hands and feet due to platelet-mediated microvascular occlusion Gout from elevated uric acid due to increased cell turnover Hypertension common comorbidity in PV Bleeding tendency paradoxically, despite elevated platelets, qualitative platelet dysfunction can cause GI bleeding Signs and symptoms that are routinely associated with a confirmed diagnosis of anemia or polycythemia (e.g., tachycardia, fatigue, pallor with anemia
Competitive binding studies demonstrate high affinity interactions with the IGF-1 receptor, exhibiting enhanced potency compared to native IGF-1 in cellular assays
Important Note: This information is provided for educational purposes only and is not medical advice
Athletes looking to amplify this signal may benefit from timing injections approximately 30-60 minutes before training sessions, a practice analogous to pre-exercise peptide protocols used with BPC-157 and TB-500, though direct timing data for MOTS-c are not yet available in peer-reviewed literature
65 found that HSYA increased NO content and inhibited the expression of endothelin-1
